These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 4036600)

  • 21. Decreased bone mineral density in experimental myasthenia gravis in C57BL/6 mice.
    Oshima M; Iida-Klein A; Maruta T; Deitiker PR; Atassi MZ
    Autoimmunity; 2017 Sep; 50(6):346-353. PubMed ID: 28850269
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Immunologic aspects of disorders of neuromuscular transmission. 2. Experimental autoimmune myasthenia gravis and the Lambert-Eaton myasthenic syndrome].
    Andreis I; Lovnićki TJ; Beara N; Taradi M
    Lijec Vjesn; 1994; 116(5-6):158-61. PubMed ID: 7968205
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acetylcholine receptor-induced experimental myasthenia gravis: what have we learned from animal models after three decades?
    Baggi F; Antozzi C; Toscani C; Cordiglieri C
    Arch Immunol Ther Exp (Warsz); 2012 Feb; 60(1):19-30. PubMed ID: 22159475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice.
    Klooster R; Plomp JJ; Huijbers MG; Niks EH; Straasheijm KR; Detmers FJ; Hermans PW; Sleijpen K; Verrips A; Losen M; Martinez-Martinez P; De Baets MH; van der Maarel SM; Verschuuren JJ
    Brain; 2012 Apr; 135(Pt 4):1081-101. PubMed ID: 22396395
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overexpression of rapsyn in rat muscle increases acetylcholine receptor levels in chronic experimental autoimmune myasthenia gravis.
    Martínez-Martínez P; Losen M; Duimel H; Frederik P; Spaans F; Molenaar P; Vincent A; De Baets MH
    Am J Pathol; 2007 Feb; 170(2):644-57. PubMed ID: 17255332
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The thymus in myasthenia gravis. Changes typical for the human disease are absent in experimental autoimmune myasthenia gravis of the Lewis rat.
    Meinl E; Klinkert WE; Wekerle H
    Am J Pathol; 1991 Nov; 139(5):995-1008. PubMed ID: 1951638
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acetylcholine release in diaphragm of rats with chronic experimental autoimmune myasthenia gravis.
    Kelly JJ; Lambert EH; Lennon VA
    Ann Neurol; 1978 Jul; 4(1):67-72. PubMed ID: 211931
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complement associated pathogenic mechanisms in myasthenia gravis.
    Tüzün E; Christadoss P
    Autoimmun Rev; 2013 Jul; 12(9):904-11. PubMed ID: 23537510
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.
    Cole RN; Reddel SW; Gervásio OL; Phillips WD
    Ann Neurol; 2008 Jun; 63(6):782-9. PubMed ID: 18384168
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transplacental transmission of experimental autoimmune myasthenia gravis. A morphological study.
    Arizono N; Yonezawa T; Yamaguchi K; Furukawa S
    Acta Pathol Jpn; 1983 May; 33(3):507-13. PubMed ID: 6624444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Animal models of myasthenia gravis.
    Christadoss P; Poussin M; Deng C
    Clin Immunol; 2000 Feb; 94(2):75-87. PubMed ID: 10637092
    [TBL] [Abstract][Full Text] [Related]  

  • 32. AChR-specific immunosuppressive therapy of myasthenia gravis.
    Luo J; Lindstrom J
    Biochem Pharmacol; 2015 Oct; 97(4):609-619. PubMed ID: 26215875
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Suppression of experimental autoimmune myasthenia gravis with new immunosuppressants: 15-deoxyspergualin and actinobolin.
    Ishigaki Y; Sato T; Song DL; Hayashi K; Aoyagi T
    J Neurol Sci; 1992 Oct; 112(1-2):209-15. PubMed ID: 1469434
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunomodulation of experimental autoimmune myasthenia gravis with linomide.
    Karussis DM; Lehmann D; Brenner T; Wirguin I; Mizrachi-Koll R; Sicsic C; Abramsky O
    J Neuroimmunol; 1994 Dec; 55(2):187-93. PubMed ID: 7829669
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acetylcholine receptor and thymus in experimental autoimmune myasthenia gravis and experimental myositis.
    Ueno S; Wada K; Kang J; Takahashi M; Tarui S
    Clin Exp Immunol; 1982 Dec; 50(3):563-71. PubMed ID: 7165999
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanisms of acetylcholine receptor loss from the neuromuscular junction.
    Engel AG; Fumagalli G
    Ciba Found Symp; 1982; (90):197-224. PubMed ID: 6923808
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunization of rabbits with secific components of postsynaptic membrane. Acetylcholinesterase and cholinergic receptor.
    Clementi F; Conti-Tronconi B; Berti F; Folco G
    J Neuropathol Exp Neurol; 1976; 35(6):665-78. PubMed ID: 186567
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myasthenia gravis. Current concepts.
    Gutmann L; Chou SM
    Arch Pathol Lab Med; 1976 Aug; 100(8):401-4. PubMed ID: 947303
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Engineered agrin attenuates the severity of experimental autoimmune myasthenia gravis.
    Li Z; Li M; Wood K; Hettwer S; Muley SA; Shi FD; Liu Q; Ladha SS
    Muscle Nerve; 2018 May; 57(5):814-820. PubMed ID: 29193204
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Experimental Autoimmune Myasthenia Gravis (EAMG): from immunochemical characterization to therapeutic approaches.
    Fuchs S; Aricha R; Reuveni D; Souroujon MC
    J Autoimmun; 2014 Nov; 54():51-9. PubMed ID: 24970384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.